Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × TAK-901 × Clear all
NCT00807677 2013-07-02

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
31 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Blast Crisis, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis